This is what my son, Eric, is working on.
Judgment day nears for Alnylam and a new technology
Soon-to-be released clinicial trial data will reveal much about the Cambridge biotech’s future — as well as RNAi drug development
A $7 billion market valuation and the credibility of the entire field of RNA interference drug development is riding on the results of Alnylam Pharmaceuticals’ [[ALNY1) next big clinical trial. No pressure, folks.
edafan
Bookmarks